Evaluación y tratamiento | 27 JUL 21

Enfermedad renal crónica en adultos

El riesgo aumenta con la edad y comorbilidades como la hipertensión, la diabetes y la enfermedad cardiovascular
Autor/a: Anna Forbes, Hugh Gallagher Clinical Medicine Vol. 20. 2020 No.l:: 128,32
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

1 Roderick P , Roth M , Mindell J . Prevalence of chronic kidney disease in England: Findings from the 2009 Health Survey for England . J Epidemiol Community Health 2011 ;  65 : A12

2 Muntner P, He J , Hamm L, Loria C , Whelton PK . Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States . J Am Soc Nephrol 2002 ; 13 : 745 .

3 Kerr M , Bray B , Medcalf J , O'Donoghue DJ , Matthews B . Estimating the financial cost of chronic kidney disease to the NHS in England  Nephrology Dialysis Transplantation 2012 ; 27 : 73 – 80.

National Institute for Health and Care Excellence . Chronic kidney disease in adults: assessment and management: Clinical guideline

[CG182] . NICE , 2014 .

5 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Working Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease . Kidney Int Suppl 2013; 3: 1– 150.

6 Jacobson HR . Chronic renal failure: pathophysiology . Lancet 1991 ; 338 : 419 .

7 Kunz R , Friedrich C , Wolbers M , Mann JF . Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease . Ann Intern Med 2008 ; 148 : 30 .

8 Lv J , Ehteshami P , Sarnak MJ et al . Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis . CMAJ 2013 ; 185 : 949 – 57 .

9 Jafar TH , Stark PC , Schmid CH et al . Progression of chronic kidney disease: Blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition . Ann Intern Med 2003 ; 139 : 244 – 52 .

10 Berl T , Hunsicker LG , Lewis JB et al . Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial . J Am Soc Nephrol 2005 ; 16 : 2170.

11 Keane WF , Brenner BM , de Zeeuw D et al . The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study . Kidney Int 2003 ; 63 : 1499 .

12 de Zeeuw D , Remuzzi G , Parving HH et al . Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL . Kidney Int 2004 ; 65 : 2309.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022